116 related articles for article (PubMed ID: 30608664)
21. Preclinical evaluation of gastrin derivatives labelled with 111In: radiolabelling, affinity profile and pharmacokinetics in rats.
Melicharova L; Laznickova A; Laznicek M
Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2014 Dec; 158(4):544-51. PubMed ID: 24108197
[TBL] [Abstract][Full Text] [Related]
22. Cholecystokinin-B/Gastrin receptor-targeting peptides for staging and therapy of medullary thyroid cancer and other cholecystokinin-B receptor-expressing malignancies.
Behr TM; Béhé MP
Semin Nucl Med; 2002 Apr; 32(2):97-109. PubMed ID: 11965605
[TBL] [Abstract][Full Text] [Related]
23. Cholecystokinin 2 Receptor Agonist
Rottenburger C; Nicolas GP; McDougall L; Kaul F; Cachovan M; Vija AH; Schibli R; Geistlich S; Schumann A; Rau T; Glatz K; Behe M; Christ ER; Wild D
J Nucl Med; 2020 Apr; 61(4):520-526. PubMed ID: 31519804
[TBL] [Abstract][Full Text] [Related]
24. Triazolo-Peptidomimetics: Novel Radiolabeled Minigastrin Analogs for Improved Tumor Targeting.
Grob NM; Häussinger D; Deupi X; Schibli R; Behe M; Mindt TL
J Med Chem; 2020 May; 63(9):4484-4495. PubMed ID: 32302139
[TBL] [Abstract][Full Text] [Related]
25. (99m)Tc-labeled gastrins of varying peptide chain length: Distinct impact of NEP/ACE-inhibition on stability and tumor uptake in mice.
Kaloudi A; Nock BA; Lymperis E; Krenning EP; de Jong M; Maina T
Nucl Med Biol; 2016 Jun; 43(6):347-54. PubMed ID: 27260775
[TBL] [Abstract][Full Text] [Related]
26. Use of polyglutamic acids to reduce uptake of radiometal-labeled minigastrin in the kidneys.
Béhé M; Kluge G; Becker W; Gotthardt M; Behr TM
J Nucl Med; 2005 Jun; 46(6):1012-5. PubMed ID: 15937313
[TBL] [Abstract][Full Text] [Related]
27. Improved kinetic stability of DTPA- dGlu as compared with conventional monofunctional DTPA in chelating indium and yttrium: preclinical and initial clinical evaluation of radiometal labelled minigastrin derivatives.
Béhé M; Becker W; Gotthardt M; Angerstein C; Behr TM
Eur J Nucl Med Mol Imaging; 2003 Aug; 30(8):1140-6. PubMed ID: 12768330
[TBL] [Abstract][Full Text] [Related]
28. Improving the In Vivo Profile of Minigastrin Radiotracers: A Comparative Study Involving the Neutral Endopeptidase Inhibitor Phosphoramidon.
Kaloudi A; Nock BA; Lymperis E; Krenning EP; de Jong M; Maina T
Cancer Biother Radiopharm; 2016 Feb; 31(1):20-8. PubMed ID: 26844849
[TBL] [Abstract][Full Text] [Related]
29. Comparison of the binding and internalization properties of 12 DOTA-coupled and ¹¹¹In-labelled CCK2/gastrin receptor binding peptides: a collaborative project under COST Action BM0607.
Aloj L; Aurilio M; Rinaldi V; D'ambrosio L; Tesauro D; Peitl PK; Maina T; Mansi R; von Guggenberg E; Joosten L; Sosabowski JK; Breeman WA; De Blois E; Koelewijn S; Melis M; Waser B; Beetschen K; Reubi JC; de Jong M
Eur J Nucl Med Mol Imaging; 2011 Aug; 38(8):1417-25. PubMed ID: 21523391
[TBL] [Abstract][Full Text] [Related]
30. Multimerization results in formation of re-bindable metabolites: A proof of concept study with FSC-based minigastrin imaging probes targeting CCK2R expression.
Summer D; Kroess A; Woerndle R; Rangger C; Klingler M; Haas H; Kremser L; Lindner HH; von Guggenberg E; Decristoforo C
PLoS One; 2018; 13(7):e0201224. PubMed ID: 30059514
[TBL] [Abstract][Full Text] [Related]
31. Cholecystokinin-B (CCK-B)/gastrin receptor targeting peptides for staging and therapy of medullary thyroid cancer and other CCK-B receptor expressing malignancies.
Béhé M; Behr TM
Biopolymers; 2002; 66(6):399-418. PubMed ID: 12658727
[TBL] [Abstract][Full Text] [Related]
32. In vitro and in vivo characterization of three 68Ga- and 111In-labeled peptides for cholecystokinin receptor imaging.
Roosenburg S; Laverman P; Joosten L; Eek A; Rutjes FP; van Delft FL; Boerman OC
Mol Imaging; 2012; 11(5):401-7. PubMed ID: 22954184
[TBL] [Abstract][Full Text] [Related]
33. Radiolabeled gastrin/CCK analogs in tumor diagnosis: towards higher stability and improved tumor targeting.
Kaloudi A; Nock BA; Krenning EP; Maina T; De Jong M
Q J Nucl Med Mol Imaging; 2015 Sep; 59(3):287-302. PubMed ID: 26158215
[TBL] [Abstract][Full Text] [Related]
34. Design of Radiolabeled Analogs of Minigastrin by Multiple Amide-to-Triazole Substitutions.
Grob NM; Schmid S; Schibli R; Behe M; Mindt TL
J Med Chem; 2020 May; 63(9):4496-4505. PubMed ID: 32302130
[TBL] [Abstract][Full Text] [Related]
35. Cholecystokinin-B/gastrin receptor binding peptides: preclinical development and evaluation of their diagnostic and therapeutic potential.
Behr TM; Béhé M; Angerstein C; Gratz S; Mach R; Hagemann L; Jenner N; Stiehler M; Frank-Raue K; Raue F; Becker W
Clin Cancer Res; 1999 Oct; 5(10 Suppl):3124s-3138s. PubMed ID: 10541353
[TBL] [Abstract][Full Text] [Related]
36. Further evidence for a C-terminal structural motif in CCK2 receptor active peptide hormones.
Stone SR; Giragossian C; Mierke DF; Jackson GE
Peptides; 2007 Nov; 28(11):2211-22. PubMed ID: 17950490
[TBL] [Abstract][Full Text] [Related]
37. Radiolabelled CCK
Novak D; Tomašič T; Krošelj M; Javornik U; Plavec J; Anderluh M; Kolenc Peitl P
ChemMedChem; 2021 Jan; 16(1):155-163. PubMed ID: 32643833
[TBL] [Abstract][Full Text] [Related]
38. Selection of radiolabeled gastrin analogs for peptide receptor-targeted radionuclide therapy.
Mather SJ; McKenzie AJ; Sosabowski JK; Morris TM; Ellison D; Watson SA
J Nucl Med; 2007 Apr; 48(4):615-22. PubMed ID: 17401100
[TBL] [Abstract][Full Text] [Related]
39. Cyclic minigastrin analogues for gastrin receptor scintigraphy with technetium-99m: preclinical evaluation.
von Guggenberg E; Sallegger W; Helbok A; Ocak M; King R; Mather SJ; Decristoforo C
J Med Chem; 2009 Aug; 52(15):4786-93. PubMed ID: 19591486
[TBL] [Abstract][Full Text] [Related]
40. Improved Tumor-Targeting with Peptidomimetic Analogs of Minigastrin
Grob NM; Schibli R; Béhé M; Mindt TL
Cancers (Basel); 2021 May; 13(11):. PubMed ID: 34071914
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
